Analytical validation of a novel bioassay for thyroid-stimulating immunoglobulin.

IF 3.9 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Frontiers in Endocrinology Pub Date : 2025-01-07 eCollection Date: 2024-01-01 DOI:10.3389/fendo.2024.1468768
Paul D Olivo, Hannah Kim, Lynn Miao, Jeffery A Houtz, George J Kahaly
{"title":"Analytical validation of a novel bioassay for thyroid-stimulating immunoglobulin.","authors":"Paul D Olivo, Hannah Kim, Lynn Miao, Jeffery A Houtz, George J Kahaly","doi":"10.3389/fendo.2024.1468768","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A novel and rapid cell-based bioassay, Turbo TSI, for measurement of thyroid-stimulating immunoglobulins (TSI) was recently reported. An assessment of the analytical performance of this TSI bioassay is described herein.</p><p><strong>Methods: </strong>Thawed cells from Turbo TSI kits were treated with different concentrations of a World Health Organization (WHO) international standard (IS) TSI-positive serum. TSI was measured as a function of luciferase activity measured as relative light units (RLU) and converted into international units per liter (IU/L). Analytical performance studies were performed on numerous samples, over multiple days, by two users at two sites.</p><p><strong>Results: </strong>The limit of blank, limit of detection and limit of quantitation were determined to be 0.007 IU/L, 0.014 IU/L, and 0.021 IU/L, respectively. Receiver operator characteristics (ROC) analysis determined the cut-off to be 0.0241 IU/L with an area under the curve of 0.984. The linear range was shown to be from 0.015 to 11.958 IU/L. The intra-laboratory precision was ≤15%CV. The overall reproducibility of the assay was ≤20%CV for five concentrations (0.06 to 5.16 IU/L). Interference and cross reactivity studies with a variety of substances showed that the assay was robust. The Turbo TSI bioassay demonstrated 95.2% (95% CI 83.3-98.1) positive percent agreement and 94.8% (95% CI 90.9-97.1) negative percent agreement with an FDA-cleared bioassay (Thyretain <b><sup>®</sup></b> TSI) using serum from 295 patients with autoimmune thyroid disease.</p><p><strong>Conclusions: </strong>The Turbo TSI bioassay exhibits excellent analytical performance and a high level of reproducibility. The performance compared well with Thyretain <b><sup>®</sup></b> TSI, an FDA-cleared TSI bioassay.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"15 ","pages":"1468768"},"PeriodicalIF":3.9000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11746106/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2024.1468768","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A novel and rapid cell-based bioassay, Turbo TSI, for measurement of thyroid-stimulating immunoglobulins (TSI) was recently reported. An assessment of the analytical performance of this TSI bioassay is described herein.

Methods: Thawed cells from Turbo TSI kits were treated with different concentrations of a World Health Organization (WHO) international standard (IS) TSI-positive serum. TSI was measured as a function of luciferase activity measured as relative light units (RLU) and converted into international units per liter (IU/L). Analytical performance studies were performed on numerous samples, over multiple days, by two users at two sites.

Results: The limit of blank, limit of detection and limit of quantitation were determined to be 0.007 IU/L, 0.014 IU/L, and 0.021 IU/L, respectively. Receiver operator characteristics (ROC) analysis determined the cut-off to be 0.0241 IU/L with an area under the curve of 0.984. The linear range was shown to be from 0.015 to 11.958 IU/L. The intra-laboratory precision was ≤15%CV. The overall reproducibility of the assay was ≤20%CV for five concentrations (0.06 to 5.16 IU/L). Interference and cross reactivity studies with a variety of substances showed that the assay was robust. The Turbo TSI bioassay demonstrated 95.2% (95% CI 83.3-98.1) positive percent agreement and 94.8% (95% CI 90.9-97.1) negative percent agreement with an FDA-cleared bioassay (Thyretain ® TSI) using serum from 295 patients with autoimmune thyroid disease.

Conclusions: The Turbo TSI bioassay exhibits excellent analytical performance and a high level of reproducibility. The performance compared well with Thyretain ® TSI, an FDA-cleared TSI bioassay.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种新的促甲状腺免疫球蛋白生物测定方法的分析验证。
背景:最近报道了一种新的基于细胞的快速生物测定方法,Turbo TSI,用于测量促甲状腺免疫球蛋白(TSI)。本文描述了对TSI生物测定法分析性能的评估。方法:用不同浓度的世界卫生组织(WHO)国际标准(IS) TSI阳性血清处理Turbo TSI试剂盒解冻后的细胞。TSI作为荧光素酶活性的函数测量,以相对光单位(RLU)测量,并转换为国际单位每升(IU/L)。两名用户在两个地点对大量样品进行了多天的分析性能研究。结果:空白限为0.007 IU/L,检测限为0.014 IU/L,定量限为0.021 IU/L。受试者操作特征(ROC)分析确定其截止值为0.0241 IU/L,曲线下面积为0.984。其线性范围为0.015 ~ 11.958 IU/L。实验室内精密度≤15%CV。在5个浓度(0.06 ~ 5.16 IU/L)下,该方法的总重现性≤20%CV。对多种物质的干扰和交叉反应性研究表明,该方法是可靠的。使用295名自身免疫性甲状腺疾病患者的血清,Turbo TSI生物测定显示95.2% (95% CI 83.3-98.1)阳性,94.8% (95% CI 90.9-97.1)阴性,与fda批准的生物测定(Thyretain®TSI)一致。结论:Turbo TSI生物测定法具有优良的分析性能和高的重现性。性能与Thyretain®TSI (fda批准的TSI生物测定法)相比良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Endocrinology
Frontiers in Endocrinology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.70
自引率
9.60%
发文量
3023
审稿时长
14 weeks
期刊介绍: Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series. In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology. Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.
期刊最新文献
Association between neutrophil-to-lymphocyte ratio and left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus. Association between the triglyceride/high-density lipoprotein (TG/HDL) ratio and incidence of gout: A nationwide cohort study. Corrigendum: Evaluation of the risk of hypothyroidism and its clinical manifestations using the Zulewski scale. Editorial: Integrated multi-omic studies of metabolic syndrome, diabetes and insulin-related disorders: mechanisms, biomarkers, and therapeutic targets. Evaluating the impact of visceral fat on the outcomes of frozen embryo transfer via bioelectrical impedance analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1